UBS Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-57
Closed -$1K – 7951
2015
Q4
$1K Hold
57
– – ﹤0.01% 8155
2015
Q3
$3K Hold
57
– – ﹤0.01% 7946
2015
Q2
$4K Sell
57
-514
-90% -$43.1K ﹤0.01% 7979
2015
Q1
$39K Sell
571
-58
-9% -$4.97K ﹤0.01% 6278
2014
Q4
$58K Buy
+629
New +$65K ﹤0.01% 6300

Other funds holding MDGL

UBS Group's MDGL Position: Q3 2026 in Review

UBS Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 49% in Q3 2026, selling an estimated $104M and leaving 204,392 shares worth $103M. The position accounts for 0.01% of the portfolio, ranked #1076.

UBS Group first reported a position in MDGL in Q4 2014 and has held it in 47 quarters since. The position peaked at $216M in Q2 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • UBS Group held 204,392 shares of Madrigal Pharmaceuticals worth $103M as of Q3 2026.
  • UBS Group sold 197,316 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $104M.
  • Madrigal Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q3 2026, its #1076 holding.
  • UBS Group first reported a position in Madrigal Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Madrigal Pharmaceuticals position peaked at $216M in Q2 2026.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.